EU-MASCARA-Marcadores para la evaluación del riesgo cardiovascular subclínico

  • Investigador principal: Javier Díez Martínez                                               

  • Organismo de financiación: Comisión Europea - 7º Programa Marco

  • Dotación financiera: 311 555 €                                                                   


EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analyzing a panel of biomarkers. EU-MASCARA aims to examine genetic, proteomic and metabolomics markers together with markers of inflammation, oxidative stress and cardiac remodeling to study their incremental diagnostic and predictive value over and above existing diagnostic and predictive algorithms.

For this purpose a large number of cohorts from different European regions, both patient and population cohorts, that have been accurately assessed for cardiovascular phenotypes are readily available to the consortium. Access to clinical samples and to standardized cardiovascular phenotypes will be granted by a strong clinical platform as one of the key work packages of EU-MASCARA. Both cross-sectional and prospective analyses will be performed that will result in the development of improved risk prediction scores.

The consortium is heavily supported by contributions of SMEs in key areas of the proposed research: biomarker testing, data handling and analysis, assay development and project management. EU-MASCARA is further characterized by a strong integrative approach both within and across work packages, with results from one task informing strategies of research in other tasks. With a dedicated bioinformatics and health economic platform the most robust biomarkers will be selected and analyzed for their benefit in clinical practice. EU-MASCARA will rigorously validate biomarkers that have been proposed to be associated with cardiovascular disease and risk across different disease entities and also in independent general population samples. The most robust biomarkers will be implemented in novel biochip based assays for clinical use.

University of Glasgow; Medizinische Universitaet Graz; Emergentec Biodevelopment GMBH; Katholieke Universiteit Leuven; Medizinische Hoschchule Hannover; CHARITE-UniversitaetsMedizin Berlin; Mosaiques Diagnostics GMBH; Istituto Auxologico Italiano; Universita degli Studi di Milano-Biocca NIVERSITA' DEGLI STUDI DI MILANO-BICOCCA; Universiteit Maastricht; ACS Biomarker; Fundación Investigación Biomédica, Clínico Universidad de Valencia; Kite Innovation (Europe) Limited; Randox Clinics Limited